



UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BUSSE *et al.*

Appl. No.: 09/675,650

Filed: September 29, 2000

For: **PCA3 Messenger RNA Species in  
Benign and Malignant Prostate  
Tissues**

Confirmation No.: 1706

Art Unit: 1642

Examiner: Yu, Misook

Atty. Docket: 1619.0080001/JAG/CMB

**Amendment and Reply Under 37 C.F.R. § 1.114**

***Mail Stop RCE***

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action ("OA") dated October 27, 2004 and the Advisory Action dated August 23, 2005, in connection with the above-identified patent application, please consider the following Amendments and Remarks.

It is not believed that extensions of time or other fees are required beyond those that may otherwise be provided for in documents accompanying this paper. If, however, additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor, including fees for net addition of claims, are hereby authorized to be charged to Deposit Account No. 19-0036.

This Amendment and Reply is provided in the following format:

- (A) Each section begins on a separate sheet;  
(B) Starting on a separate sheet, a complete listing of all of the claims:

- in ascending order;
- with status identifiers; and
- with markings in the currently amended claims;

- (C) Starting on a separate sheet, the Remarks.